Boston, MA -- (SBWIRE) -- 10/11/2013 -- Global Markets Direct's, 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anemia.
- A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Johnson & Johnson, Hospira, Inc., Medgenics Inc., AMAG Pharmaceuticals, Inc., Medinox, Inc., Amgen Inc., Eli Lilly and Company, GlaxoSmithKline plc, Sangart, Inc., Rockwell Medical Technologies, Inc., Daiichi Sankyo Company, Ltd, Lentigen Corporation, Sangamo BioSciences, Inc., Gamida Cell Ltd., FibroGen, Inc., Reliance Life Sciences Pvt. Ltd., Novartis AG, Astellas Pharma Inc., Chong Kun Dang Pharmaceutical, Dong-A Pharmaceutical Co., Ltd., Japan Tobacco Inc., Sandoz GmbH, ViroPharma Incorporated, Zydus Cadila Healthcare Limited, Bayer AG, Zosano Pharma, Inc., 3SBio Inc., Evotec Aktiengesellschaft, Ligand Pharmaceuticals Incorporated, PROLOR Biotech, Inc., ReGenX Biosciences, LLC, Accentia Biopharmaceuticals, Inc., ADVENTRX Pharmaceuticals, Alexion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc, Zenotech Laboratories Limited, ProMetic Life Sciences Inc., Lipoxen PLC, Boryung Pharmaceutical Co., Ltd., Green Cross Corporation, Hanall Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd., CCM Duopharma Biotech Bhd., Pluristem Therapeutics Inc., Uni-Bio Science Group Ltd., Panacea Biotec Limited, Affymax, Inc., Panion & Bf Biotech Inc., Myungmoon pharmaceutical Co.,Ltd., Cellerant Therapeutics, Inc., Advinus Therapeutics Pvt. Ltd., Asterion Ltd, CIMAB S.A., Prolong Pharmaceuticals, Acceleron Pharma, Inc., SynZyme Technologies, LLC, Pieris AG, Xenon Pharmaceuticals Inc., ERYtech Pharma, Archemix Corp., HemaQuest Pharmaceuticals, Inc., Akebia Therapeutics, Inc., GENETIX Pharmaceuticals, Inc., NOXXON Pharma AG, Morphogenesis, Inc., NKT Therapeutics, Inc., Bolder Biotechnology, Inc., Palkion, Inc., Acetylon Pharmaceuticals, Inc., Emmaus Medical, Inc., Avesthagen Limited, PharmaEssentia Corporation, Vifor Pharma Ltd., AesRx, LLC., Errant Gene Therapeutics, LLC, NAL Pharmaceuticals Ltd.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Influenza - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
- Asthma - Pipeline Review, H2 2013
- Prostate Cancer - Pipeline Review, H2 2013
- Type 2 Diabetes - Pipeline Review, H2 2013
- Stroke - Pipeline Review, H2 2013
- Crohn's Disease - Pipeline Review, H2 2013
- Macular Degeneration - Pipeline Review, H2 2013
- Schizophrenia - Pipeline Review, H2 2013
- Kidney Disease - Pipeline Review, H2 2013